相关临床试验
0
0 进行中
药物批准
99
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
<p><strong>4. INDICATIONS</strong></p> <p><u>Hypertension</u><br> LOSARTAN-TEVA is indicated for the treatment of hypertension.</p> <p><u>Hypertensive Patients with Left Ventricular Hypertrophy</u><br> LOSARTAN-TEVA is indicated for the reduction in the risk of stroke in hypertensive patients with left ventricular hypertrophy (see RACE – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p><u>Renal Protection in Type 2 Diabetic Patients with Proteinuria</u><br> LOSARTAN-TEVA is indicated to delay the progression of renal disease as measured by a reduction in the incidence of doubling of serum creatinine and end stage renal disease (need for dialysis or renal transplantation), and to reduce proteinuria.</p>
<p><strong>4.1. Therapeutic indications</strong><br> Treatment of erectile dysfunction (ED) in adult males. In order for tadalafil to be effective for the treatment of ED, sexual stimulation is required.</p> <p>Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). If Tadalafil is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks.</p> <p>Treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED/BPH).</p> <p>Tadalafil is not indicated for use by women.</p>
<p><strong>4.1. Therapeutic indications</strong><br> Treatment of erectile dysfunction (ED) in adult males. In order for tadalafil to be effective for the treatment of ED, sexual stimulation is required.</p> <p>Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). If Tadalafil is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks.</p> <p>Treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED/BPH).</p> <p>Tadalafil is not indicated for use by women.</p>
**4 INDICATIONS AND USAGE** Dasatinib is indicated for the treatment of adult patients with - newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. - chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy including imatinib. - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib is indicated for the treatment of pediatric patients with - newly diagnosed Ph+ CML in chronic phase or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. - newly diagnosed Ph+ ALL in combination with chemotherapy.
**4 INDICATIONS AND USAGE** Dasatinib is indicated for the treatment of adult patients with - newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. - chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy including imatinib. - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib is indicated for the treatment of pediatric patients with - newly diagnosed Ph+ CML in chronic phase or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. - newly diagnosed Ph+ ALL in combination with chemotherapy.
暂无资讯文章
